Viewing Study NCT03748732


Ignite Creation Date: 2025-12-24 @ 9:24 PM
Ignite Modification Date: 2026-01-04 @ 4:55 PM
Study NCT ID: NCT03748732
Status: UNKNOWN
Last Update Posted: 2018-11-21
First Post: 2018-11-18
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Extensive Circumferential Partial Thickness Sclerectomy in Nanophthalmic Eyes
Sponsor: Rafic Hariri University Hospital
Organization:

Study Overview

Official Title: Extensive Circumferential Partial Thickness Sclerectomy in Nanophthalmic Eyes
Status: UNKNOWN
Status Verified Date: 2018-11
Last Known Status: ACTIVE_NOT_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Purpose: To describe an extensive scleral excision technique to treat or prevent uveal effusion in nanophthalmic eyes.

Design: Prospective interventional case series.

Methods:

* Setting: Institutional.
* Patient Population: Consecutive patients with nanophthalmos were operated on by one surgeon.
* Intervention Procedure: A single, 90% thickness scleral window extending from immediately behind the extraocular muscle insertions to the vortex veins was performed for 3 and 1/4 quadrants as a circumferential strip.
* Main Outcome Measure: Resolution or prevention of uveal effusion.
Detailed Description: Surgical Technique All surgeries were performed under general anesthesia by one surgeon (AMM). Because the majority of the patients were young with narrow palpebral fissures and very deep set globes in small orbits, special surgical techniques were required. Lateral canthotomy was performed on all patients except for the first. Limbal 360o conjunctival peritomy was followed by securing of each rectus muscles with a modified muscle hook and 2-0 silk suture. Scleral dissection was performed from immediately behind to the muscle insertions posterior to the vortex veins. A 90% depth scleral window was excised over 3 and ΒΌ quadrants, excluding 3/4 of the superior temporal quadrant to avoid damaging the superior oblique muscle.

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: